NCT02257632View on ClinicalTrials.gov

Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

PHASE4CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 8, 2015

Primary Completion Date

March 20, 2017

Study Completion Date

June 8, 2017

Conditions
Wet Age-Related Macular Degeneration
Interventions
DRUG

Ranibizumab 0.5 mg

Administered as an intravitreal injection

DRUG

Aflibercept 2 mg

Administered as an intravitreal injection

Trial Locations (6)

35039

Novartis Investigative Site, Marburg

49076

Novartis Investigative Site, Osnabrück

50924

Novartis Investigative Site, Cologne

80336

Novartis Investigative Site, München

81675

Novartis Investigative Site, München

93042

Novartis Investigative Site, Regensburg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY